Which Is Better: Wegovy or Mounjaro for Weight Loss?

Last reviewed: June 17, 2026

Last updated: June 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy (semaglutide) and Mounjaro (tirzepatide) are both FDA-approved injectable medications for weight loss, but they work through different biological pathways. Tirzepatide, the active compound in Mounjaro, activates both GLP-1 and GIP receptors, while semaglutide targets only the GLP-1 receptor, potentially explaining differences in weight reduction outcomes observed across clinical trials.

How Semaglutide and Tirzepatide Differ at the Cellular Level

Semaglutide, the medication in Wegovy, binds selectively to GLP-1 receptors in the brain and pancreas, slowing gastric emptying and promoting satiety. Tirzepatide, found in Mounjaro, activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, creating a dual-action mechanism that may enhance insulin secretion and energy expenditure more broadly.

The dual-receptor activation of tirzepatide theoretically offers a more comprehensive metabolic intervention. By engaging both pathways, tirzepatide may address appetite control and blood sugar regulation through overlapping but distinct neural and hormonal circuits, distinguishing it fundamentally from single-pathway semaglutide therapy.

Weight Loss Results: Clinical Trial Data and Real-World Outcomes

The STEP trials for semaglutide demonstrated an average weight loss of 15% of body weight over 68 weeks in participants receiving the highest dose (2.4 mg weekly). The SURMOUNT trials for tirzepatide showed approximately 21% weight loss at the maximum dose (15 mg weekly) over 72 weeks, suggesting a numerically greater reduction, though patient populations and trial designs differ.

Individual responses to both medications vary widely based on genetics, lifestyle, and metabolic factors. Some patients respond exceptionally well to semaglutide alone, while others achieve superior outcomes with tirzepatide's dual-mechanism approach. Neither medication guarantees identical results across all users, making personalized assessment essential for selecting the right therapy.

Side Effect Profiles and Tolerability Differences

Both semaglutide and tirzepatide commonly cause gastrointestinal effects including nausea, vomiting, and constipation, particularly during dose escalation phases. Tirzepatide users report slightly higher rates of nausea in clinical trials, though many symptoms diminish as the body adapts over weeks to months of consistent treatment.

Pancreatitis risk, though rare, has been documented with both GLP-1 agonists and requires monitoring in patients with personal or family history of pancreatic disease. Hypoglycemia occurs primarily when these medications are combined with insulin or sulfonylureas, making medication review with a healthcare provider crucial before starting either therapy.

Choosing Between Medications: Personalized Genetic Insights Matter

Genetic variations in GLP-1 receptor sensitivity (GLP1R rs6923761) and GIP receptor function (GIPR rs1800437) influence individual medication response, yet most patients never receive this information. PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways and 49 peptides, identifying genetic predispositions to GLP-1 or GIP receptor responsiveness that can guide medication selection toward the approach most aligned with your biology.

Beyond genetics, factors like existing kidney function, personal pancreatitis history, gastrointestinal tolerance, and treatment cost influence the optimal choice. Compounded tirzepatide injections through PlexusDx start at $249 per month with a flat-rate pricing model—your dose may increase without affecting your monthly payment—offering a more affordable entry point than branded Mounjaro for patients seeking dual-mechanism therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide stronger than semaglutide for weight loss?

Clinical trials suggest tirzepatide produces greater average weight loss (approximately 21% vs. 15% at maximum doses), though individual responses vary significantly. The dual GLP-1 and GIP receptor activation may offer enhanced metabolic benefits for some patients, but semaglutide alone remains highly effective for others. Genetic testing and medical history should guide the choice.

Can I switch from Wegovy to Mounjaro if I'm not seeing results?

Yes, switching between GLP-1 agonists is medically feasible and sometimes recommended when one medication plateaus or causes intolerable side effects. However, direct cross-switching requires careful dose titration and medical supervision to prevent adverse events. PlexusDx providers can assess whether a medication change aligns with your health profile and genetic predispositions.

How much does compounded tirzepatide cost compared to brand-name Mounjaro?

PlexusDx compounded tirzepatide injections start at $249 per month flat-rate pricing, regardless of dose level. This contrasts sharply with brand Mounjaro's significantly higher out-of-pocket costs even with insurance. Both medications use the same active compound; compounding through licensed 503A pharmacies simply reduces manufacturing and distribution overhead.

Which medication is safer: semaglutide or tirzepatide?

Both medications carry similar safety profiles, with the most common side effects being gastrointestinal and generally manageable during dose escalation. Rare but serious risks include pancreatitis and gallbladder issues with either therapy. Individual safety depends on medical history, kidney function, and concomitant medications—a conversation with your healthcare provider is essential before starting either drug.

How does genetic testing help me choose between these medications?

The PlexusDx Precision Peptide Genetic Test identifies variants in GLP1R and GIPR genes that correlate with individual receptor sensitivity and medication response patterns. For example, specific GLP1R rs6923761 variants may predict stronger semaglutide responsiveness, while GIPR rs1800437 variants may indicate better outcomes with tirzepatide's dual-pathway approach. Testing costs $99 after your first month of treatment and provides data-driven guidance for optimizing your therapy.

Related Reading

• Wegovy For Weight Loss 2
• Mounjaro For Weight Loss 2
• Wegovy Weight Loss Pills
• Weight Loss Mounjaro

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.